Cervical Cancer in Kenya: Statistics, Screening, Complications, and What Every Woman Needs to Know

A factual, evidence-based guide for Kenyan women, caregivers, and health advocates:

Cervical cancer is one of Kenya's most serious and preventable public health crises. It is the leading cause of cancer-related death among Kenyan women — not because it is untreatable, but because most women are diagnosed at a late stage, when the options for cure are far more limited.

This article brings together the latest data on the prevalence of cervical cancer in Kenya, what causes it, how it is screened and treated, the serious complications that develop when it goes untreated, and — crucially — what can be done to prevent it. Every fact cited here comes from peer-reviewed research, official Ministry of Health documents, WHO data, or national surveys.

1. Cervical cancer in Kenya: the scale of the problem

How many women are affected?

The burden of cervical cancer in Kenya is among the highest in the world. According to the WHO Global Cancer Observatory, the 2023 figures paint a stark picture:

To put these numbers in context: cervical cancer is the leading cause of cancer mortality in Kenya. Every day, approximately ten Kenyan women die from a disease that is largely preventable with vaccination and detectable early through screening.

Who is most at risk?

Cervical cancer in Kenya most commonly affects women between the ages of 35 and 55, though younger women are not immune. Specific risk factors that increase a woman's likelihood of developing the disease include:

● Infection with high-risk strains of the Human Papillomavirus (HPV) — particularly types 16 and 18, which together cause approximately 70% of all cervical cancer cases globally.

● HIV-positive status: women living with HIV have a significantly weakened immune system, making them far more susceptible to persistent HPV infection and faster progression to cancer. Africa's high HIV prevalence is one reason the region carries such a disproportionate cervical cancer burden.

● Early sexual debut and multiple sexual partners, which increase the likelihood of HPV exposure.

● High parity (many pregnancies), which is associated with increased cervical cancer risk.

● Long-term use of oral contraceptives (5+ years) has been associated with a modestly increased risk in some studies.

● Smoking, which weakens local cervical immunity.

● Low socioeconomic status, which correlates with reduced access to screening and timely treatment.

Important: HPV is extremely common — an estimated 80% of sexually active people will contract HPV at some point in their lives. In most cases, the immune system clears the virus naturally within two years. Cervical cancer develops only when a high-risk HPV strain persists and is left undetected over many years. This is precisely why regular screening is so effective: it catches abnormal cells long before they become cancer.

2. What causes cervical cancer?

Virtually all cases of cervical cancer — more than 99% — are caused by persistent infection with certain strains of the Human Papillomavirus (HPV). HPV is a sexually transmitted virus with more than 200 known strains. Approximately 14 of these are classified as high-risk for cancer. Types 16 and 18 are responsible for around 70% of all cervical cancers.

The progression from HPV infection to invasive cervical cancer is slow — typically taking 10 to 15 years. This long pre-cancerous window is exactly what makes cervical cancer one of the most preventable cancers when screening programmes are functioning well. The disease passes through identifiable pre-cancerous stages (called cervical intraepithelial neoplasia, or CIN), during which abnormal cells can be detected and treated before cancer develops.

Cervical cancers are classified into two main types based on where in the cervix they originate. Squamous cell carcinoma, which accounts for 70–80% of cases, begins in the thin, flat cells lining the outer part of the cervix. Adenocarcinoma, accounting for 15–20% of cases, develops in the glandular cells of the cervical canal.

3. Cervical cancer screening in Kenya

Current screening guidelines (Kenya Ministry of Health)

The Kenya Ministry of Health Cervical Cancer Screening Guidelines (updated 2024) recommend the following for women who are HIV-negative:

● Begin screening at age 25.

● Screening methods include HPV DNA testing, Visual Inspection with Acetic Acid (VIA), Visual Inspection with Lugol's Iodine (VILI), and Pap smear.

● Screening should be repeated every 5 years if results are normal.

For women who are HIV-positive, the guidelines are more stringent:

● Begin screening earlier (from the time of HIV diagnosis or at first sexual activity).

● Screen annually, given the increased risk of rapid progression.

Screening methods used in Kenya

Kenya's public health system relies primarily on VIA because it is low-cost, provides immediate results, and can be performed by trained nurses without laboratory infrastructure. However, HPV DNA testing — the most sensitive and internationally recommended method — has not yet been routinely available in public facilities. A 2024 WHO-led initiative in partnership with Roche is working to expand access to HPV-based screening across Kenya.

The available screening options in Kenya, in order of increasing sensitivity, are:

• VIA (Visual Inspection with Acetic Acid): Diluted acetic acid (vinegar) is applied to the cervix. Pre-cancerous cells turn white — a result visible immediately to the provider. It is widely accessible and affordable but less sensitive than HPV testing.
• Pap smear (cervical cytology): Cells are collected from the cervix and examined in a laboratory. Requires trained cytologists and lab infrastructure — a barrier in many parts of Kenya.
• HPV DNA testing: The most sensitive method, directly detecting high-risk HPV strains. Self-collection (where a woman takes her own sample) is being piloted as a way to overcome access barriers. There has been no HPV testing available in public facilities in Kenya, though this is now changing through a WHO-led initiative

How much does cervical cancer screening cost in Kenya?

In public health facilities, VIA screening is offered free of charge or at very low cost (under KSh 200 in most county hospitals). However, access varies significantly by location. In private facilities, costs are considerably higher:

● VIA: approximately KSh 500–2,000 in private clinics.

● Pap smear: approximately KSh 1,500–5,000 depending on facility and location.

● HPV DNA test: KSh 3,000–8,000 where available, primarily in private laboratories.

Free cervical cancer screening campaigns have been periodically organised by the national government and NGO partners. To check for current free screening programmes in 2026, contact your nearest county health department or visit a government health facility and ask about the National Cervical Cancer Prevention Programme.

Why is screening uptake so low?

Despite guidelines being in place, only 16.81% of Kenyan women of reproductive age had been screened as of the 2022 Kenya Demographic and Health Survey. This is a critically low figure. Research has identified several overlapping barriers:

• Stigma: In many communities, cervical cancer is incorrectly associated with HIV or perceived promiscuity, causing women to avoid testing to avoid judgement
• Geography: Trained screening providers are concentrated in urban and peri-urban areas; rural women may travel hours for access
• Follow-up failures: Estimates suggest only 22–39% of women diagnosed with pre-cancerous lesions complete treatment — a critical gap that allows preventable cases to progress to cancer

4. Stages of cervical cancer

Cervical cancer is staged using the International Federation of Gynecology and Obstetrics (FIGO) system. Stage determines treatment options, prognosis, and the likelihood of complications.

• Stage I: Cancer confined entirely to the cervix. 5-year survival: 80–95% with treatment. Cure is most achievable at this stage.
• Stage II: Cancer has spread beyond the cervix to the upper vagina or nearby tissue, but not to the pelvic wall. 5-year survival: 60–80%. Still treatable with curative intent.
• Stage III: Cancer has reached the lower vagina, pelvic wall, or is blocking the ureters (the tubes draining the kidneys). 5-year survival: 30–50%.
• Stage IV: Cancer has spread to the bladder, rectum, or distant organs such as the lungs and liver. 5-year survival: 15–20%.

The crisis in Kenya: The majority of Kenyan women diagnosed with cervical cancer present at Stage III or IV — when the cancer is advanced and cure rates are dramatically lower. This is a direct consequence of the low screening coverage described above. Cervical cancer caught at Stage I or II is far more likely to be cured.

5. Complications of cervical cancer

When cervical cancer is not detected early, it causes a range of serious, often life-altering complications as the tumour grows and invades surrounding organs and structures. Understanding these complications underlines why early detection is so critical. Most of these complications occur in Stage III and IV disease.

The fistulas deserve particular attention in the Kenyan context because they disproportionately affect women who present late. A vesicovaginal fistula — where urine leaks continuously from the vagina — causes profound social isolation, as women affected often face rejection from their partners and communities due to the smell and associated stigma. In Kenya, fistula repair surgery is available at a small number of specialist centres, including Kenyatta National Hospital, but access remains limited.

6. Treatment of cervical cancer in Kenya

Treatment options

The treatment approach depends on the stage at diagnosis, the patient's overall health, available facilities, and whether preservation of fertility is a goal. In Kenya, treatment is primarily available at national and county referral hospitals.

• Surgery (Stage I–IIA): A radical hysterectomy — removal of the uterus, cervix, upper vagina, and surrounding tissue — is the primary treatment for early-stage disease. In very early cases (Stage IA), a cone biopsy may preserve fertility.
• Concurrent chemoradiation (Stage IB2–IVA): The international standard of care for locally advanced cervical cancer is external beam radiotherapy combined with cisplatin-based chemotherapy, followed by brachytherapy (internal radiotherapy delivered directly to the tumour). This is the treatment most Kenyan women require, given the late stage at which most are diagnosed.
• Palliative care (Stage IVB): For women with distant metastases, management focuses on symptom relief, pain control, and quality of life. Chemotherapy may be used to slow progression.

How much does cervical cancer treatment cost in Kenya?

The cost of treatment is catastrophic for most Kenyan families, particularly those without insurance. Published estimates give the following figures for public hospital treatment:

● Early-stage treatment (Stage I–II, surgery or chemoradiation): approximately KSh 110,000–200,000 at public hospitals.

● Advanced-stage treatment (Stage III–IV, radiotherapy + chemotherapy): can exceed KSh 500,000–1,000,000 or more, depending on duration and complications.

● In private facilities, Stage III treatment has been estimated at over KSh 750,000 (approximately USD 5,800).

● Palliative care at a health facility costs approximately KSh 8,000–10,000 per day.

The National Hospital Insurance Fund (NHIF, now restructured under SHA — Social Health Authority) covers some cancer treatment costs, but coverage is often incomplete for the full treatment cycle. Many families sell assets, use savings, or rely on community fundraising (harambee) to finance treatment.

Where is treatment available in Kenya?

● Kenyatta National Hospital (Nairobi) — the primary public referral centre, housing the largest oncology unit in the country.

● Moi Teaching and Referral Hospital (Eldoret) — major referral centre for western Kenya, with published cervical cancer outcomes data.

● Coast General Teaching and Referral Hospital (Mombasa).

● County referral hospitals in Kisumu, Nakuru, Nyeri, and other major towns offer some level of oncology services, though radiotherapy capability is limited outside Nairobi.

The scarcity of radiotherapy machines is a critical bottleneck. Kenya has a small number of functioning linear accelerators for a population of 55+ million people. Women outside Nairobi often must travel long distances and stay in Nairobi for weeks during radiotherapy, creating an enormous financial and logistical burden.

7. The HPV vaccine in Kenya

Who should be vaccinated?

The HPV vaccine prevents infection with the HPV strains responsible for the majority of cervical cancers. Kenya introduced the HPV vaccine into the national immunisation programme in 2019, targeting girls aged 10 years through school-based delivery.

The vaccine is most effective when given before a girl becomes sexually active — before any exposure to HPV. It does not treat an existing HPV infection or cervical cancer.

Current vaccination coverage

Vaccination coverage in Kenya has been inconsistent. As of 2023, approximately 28% of target girls had received the first dose, and only 24% had completed the required doses — well below the WHO's target of 90% coverage. Coverage fell slightly from 2021 levels, highlighting the ongoing challenges of vaccine delivery in a country with significant geographic and logistical barriers.

Kenya recently adopted the WHO's recommendation for a single-dose HPV vaccination schedule. Evidence shows that one dose of the HPV vaccine provides durable, strong protection against the HPV strains most responsible for cervical cancer. This policy change is expected to dramatically improve coverage by removing the logistical barrier of a two-dose schedule.

HPV vaccine cost in Kenya

● Through the national immunisation programme (school-based): Free for girls aged 10.

● In private clinics: KSh 20,000–40,000 per dose (outside government programme).

Important — funding risk: Kenya's HPV vaccination programme has historically been heavily subsidised by Gavi (the Vaccine Alliance). Kenya is in the process of graduating from Gavi support, meaning the government must progressively fund a larger share of vaccine costs — rising from 46% in 2024 to 80% in 2026 and 100% from 2027. Modelling suggests the HPV vaccine could cost KSh 14,000 per dose without donor support. This makes sustained government investment in the programme critical.

8. Kenya's cervical cancer prevention strategy

Kenya's National Cancer Control Strategy 2023–2027 and the Cervical Cancer Screening Guidelines 2024 are aligned with the WHO's 90-70-90 targets:

• 90% of girls fully vaccinated against HPV by age 15
• 70% of women screened using a high-performance test by age 35, and again by age 45
• 90% of women identified with cervical disease receiving treatment

WHO modelling estimates that if Kenya achieves these targets by 2030, cervical cancer could be eliminated as a public health problem in Kenya — and up to 1.89 million lives could be saved by 2120 compared to a scenario with no intervention.

Current programmatic progress falls significantly short of these targets, particularly on screening coverage and precancer treatment completion rates. Closing these gaps requires sustained investment in health worker training, screening infrastructure, public awareness campaigns, and treatment capacity — particularly radiotherapy.

9. Cervical cancer survivors in Kenya

Survival from cervical cancer in Kenya depends heavily on stage at diagnosis and access to treatment. A retrospective study at Moi Teaching and Referral Hospital in Eldoret found that overall two-year survival rates varied significantly by stage and HIV status.

Women diagnosed at Stage I or II who receive timely surgery or chemoradiation have significantly better outcomes. Women with bilateral hydronephrosis at diagnosis — a marker of very advanced disease — have a median overall survival of approximately 12 months.

Survivorship in Kenya carries its own challenges. Many survivors face ongoing physical consequences of treatment (bowel or bladder changes, lymphoedema, early menopause), financial hardship from treatment costs, and psychological trauma including anxiety, depression, and — in some communities — social stigma and relationship breakdown. Support groups for cervical cancer survivors exist in Nairobi and some other urban centres; access in rural areas remains very limited.

10. What every woman in Kenya should do